Drug Approval | July 22, 2024
Briefs: Zydus Lifesciences and Divi's Laboratories
Zydus receives final approval from USFDA for its NDA Zituvimeta, extended-release tablets
Zydus receives final approval from USFDA for its NDA Zituvimeta, extended-release tablets
_256_384.jpg)
€ 6.6 million investment at Nantong site expands production capabilities for cell culture media
This product will be manufactured at Lupin’s Pithampur facility in India
The Unit has been issued GMP Certification from ANVISA-Brazil
Sacubitril and Valsartan combination is used to treat chronic heart failure in adults
Diroximel Fumarate Delayed-Release Capsules is indicated for the treatment of relapsing forms of multiple sclerosis
NCIL was listed at Rs. 171 at an upper circuit premium of 90% over the fixed price band of Rs. 90
States urged to maintain a state of constant vigil through screening of pregnant women for Zika virus infection and monitoring the growth of foetus of expecting mothers who tested positive for Zika
Offering testing, treatment and support to help stop the spread of HIV and other infectious diseases
Laurus Labs receives EIR from USFDA for API facilities
Subscribe To Our Newsletter & Stay Updated
